Expression levels of induced sputum IL‑8 and IL‑10 and drug intervention effects in patients with acute exacerbated COPD complicated with chronic cor pulmonale at high altitude

Feng,Enzhi; Wan,Ronghua; Yang,Shengyue; Yan,Ziqiang; Wang,Shaolin; He,Wei; Zhang,Ying; Yin,He; Chen,Zongru; Liu,Ruinian

doi:10.3892/etm.2013.1192

Expression levels of induced sputum IL‑8 and IL‑10 and drug intervention effects in patients with acute exacerbated COPD complicated with chronic cor pulmonale at high altitude

Authors:
- Enzhi Feng
- Ronghua Wan
- Shengyue Yang
- Ziqiang Yan
- Shaolin Wang
- Wei He
- Ying Zhang
- He Yin
- Zongru Chen
- Ruinian Liu
View Affiliations

Affiliations: Center of Respiratory Medicine, The Fourth Hospital of PLA, Lanzhou Command, Xining, Qinghai 810007, P.R. China, Department of Cardiovascular Surgery, Heart Center, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
Published online on: July 1, 2013 https://doi.org/10.3892/etm.2013.1192
Pages: 747-752

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to assess the expression levels of induced sputum interleukin (IL)‑8 and IL‑10 levels in patients with acute exacerbated chronic obstructive pulmonary disease (AECOPD) complicated with chronic cor pulmonale (CCP) at high altitude, and to evaluate the intervention effects of an inhaled corticosteroid (ICS) and a β2‑adrenoceptor agonist in this disease. A total of 186 patients with AECOPD complicated with CCP were randomly divided into three groups, with 62 cases in each. With regard to the two treatment groups, group A was treated with salmeterol/fluticasone (50 µg/250 µg, respectively) by airway inhalation twice daily, while group B received budesonide (1 mg) as a spray inhalation, twice daily. The routine treatment group (group C) received only routine treatment. The levels of IL‑8 and IL‑10 in the induced sputum and the predicted percentage of forced expiratory volume in one second (FEV1%pred), partial pressure of oxygen in arterial blood (PaO2) and partial pressure of carbon dioxide in arterial blood (PaCO2) were examined on admission and at a stable stage two weeks following treatment. Forty healthy volunteers served as a control group (group D). Compared with group D values, the IL‑8 induced sputum level and the PaCO2 were significantly increased, while the level of IL‑10, FEV1%pred and the PaO2 were markedly decreased in the three COPD groups prior to treatment. Following treatment, the induced sputum IL‑8 level and the PaCO2 were significantly decreased, while the induced sputum IL‑10 level, FEV1%pred and the PaO2 were markedly increased in the three treatment groups compared with the values pre‑therapy (all P<0.01). The post‑treatment parameters were significantly different among the three groups (P<0.01). The results indicate that IL‑8 and IL‑10 are involved in the airway inflammation of AECOPD complicated by CCP. Treatment with an ICS was demonstrated to be a successful method of reducing the local expression of IL‑8 and increasing the local expression of IL‑10; however, ICS combined with a long‑acting β2‑adrenoceptor agonist (LABA) was more effective than the sole administration of ICS in patients with AECOPD complicated by CCP at high altitude.

View Figures

View References

1	Agustí A and Vestbo J: Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 184:507–513. 2011.PubMed/NCBI
2	Dalal AA, Liu F and Riedel AA: Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. Int J Chron Obstruct Pulmon Dis. 6:533–542. 2011. View Article : Google Scholar
3	Lopez AD, Shibuya K, Rao C, et al: Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 27:397–412. 2006. View Article : Google Scholar : PubMed/NCBI
4	Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 176:532–555. 2007. View Article : Google Scholar : PubMed/NCBI
5	Parr DG, White AJ, Bayley DL, Guest PJ and Stockley RA: Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res. 7:1362006. View Article : Google Scholar : PubMed/NCBI
6	GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Revised 2011) [EB/OL]. http://www.goldcopd.comuri. Accessed February 22, 2012
7	Asadullah K, Sterry W and Volk HD: Interleukin-10 therapy - review of a new approach. Pharmacol Rev. 55:241–269. 2003. View Article : Google Scholar : PubMed/NCBI
8	Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB and Temel I: Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med. 100:846–854. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ko FW, Leung TF, Wong GW, et al: Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 4:79–86. 2009.
10	O’Donnell R, Breen D, Wilson S and Djukanovic R: Inflammatory cells in the airways in COPD. Thorax. 61:448–454. 2006.
11	Kochetkova EA, Volkova MV, Surovenko TN and Gel’tser BI: Cytokine status in patients with chronic obstructive pulmonary diseases and its relationship with bone tissue functional state. Ter Arkh. 76:23–27. 2004.(In Russian).
12	Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 356:775–789. 2007. View Article : Google Scholar : PubMed/NCBI
13	COPD Working Group of Chinese Medical Association respiratory disorder branch. Guidelines for the Diagnosis and Treatment of COPD (2007 Revised Edition). Chin J Tuberc Respir Dis. 30:8–17. 2007.(In Chinese).
14	Chen HZ: Practical Internal Medicine. 11th edition. People’s Health Publishing House; Beijing: pp. 1449–1452. 2001
15	Oudin S and Pugin J: Role of MAP kinase activation in interleukin-8 production by human BEAS-2B bronchial epithelial cells submitted to cyclic stretch. Am J Respir Cell Mol Biol. 27:107–114. 2002. View Article : Google Scholar : PubMed/NCBI
16	Powrie DJ, Wilkinson TM, Donaldson GC, et al: Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 30:472–478. 2007. View Article : Google Scholar : PubMed/NCBI
17	Chung KF: Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy. 4:619–625. 2005. View Article : Google Scholar : PubMed/NCBI
18	Gong MN, Thompson BT, Williams PL, et al: Interleukin-10 polymorphism in position -1082 and acute respiratory distress syndrome. Eur Respir J. 27:674–681. 2006. View Article : Google Scholar : PubMed/NCBI
19	Wilson SJ, Wallin A, Della-Cioppa G, Sandström T and Holgate ST: Effect of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med. 164:1047–1052. 2001. View Article : Google Scholar : PubMed/NCBI
20	Kersul AL, Iglesias A, Ríos Á, et al: Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 47:176–183. 2011. View Article : Google Scholar : PubMed/NCBI
21	Takanashi S, Hasegawa Y, Kanehira Y, et al: Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J. 14:309–314. 1999. View Article : Google Scholar : PubMed/NCBI
22	Burgess JL, Nanson CJ, Hysong TA, Gerkin R, Witten ML and Lantz RC: Rapid decline in sputum IL-10 concentration following occupational smoke exposure. Inhal Toxicol. 14:133–140. 2002. View Article : Google Scholar : PubMed/NCBI
23	Liu SX, Zhang GJ, Wang HQ, Chen SS and Chu HY: Effect of inhaled glucocorticoids/long-acting β2-agonist on chronic obstructive pulmonary disease. International Journal of Respiration. 29:129–131. 2009.(In Chinese).
24	Barnes NC, Qiu YS, Pavord ID, et al; SCO30005 Study Group. Antiinflammatory effects of salmeterol/formoterol propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 173:736–743. 2006. View Article : Google Scholar : PubMed/NCBI
25	Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R and Hamid Q: Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 62:938–943. 2007. View Article : Google Scholar : PubMed/NCBI
26	Celli BR, Thomas NE, Anderson JA, et al: Effect of pharmacotherapy on rate of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 178:332–338. 2008. View Article : Google Scholar : PubMed/NCBI
27	Fenton C and Keating GM: Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease. Drugs. 64:1975–1996. 2004. View Article : Google Scholar : PubMed/NCBI
28	Marwick VM and Chung KF: Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 5:297–309. 2010. View Article : Google Scholar : PubMed/NCBI
29	Patel IS, Roberts NJ, Lloyd-Owen SJ, Sapsford RJ and Wedzicha JA: Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J. 22:94–99. 2003. View Article : Google Scholar : PubMed/NCBI
30	Armstrong J, Harbron C, Lea S, et al: Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 338:732–740. 2011. View Article : Google Scholar